Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.65% | 2.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.65% | 2.36% | |||
| Cost of Revenue | -4.18% | 9.22% | |||
| Gross Profit | -1.75% | -1.30% | |||
| SG&A Expenses | -5.59% | -5.87% | |||
| Depreciation & Amortization | 1.32% | -0.16% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.77% | 2.43% | |||
| Operating Income | -1.07% | 1.33% | |||
| Income Before Tax | -774.44% | 236.39% | |||
| Income Tax Expenses | -190.98% | 3,150.00% | |||
| Earnings from Continuing Operations | -3,443.75% | 125.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3,443.75% | 125.40% | |||
| EBIT | -1.07% | 1.33% | |||
| EBITDA | -3.95% | 0.44% | |||
| EPS Basic | -3,412.00% | 125.51% | |||
| Normalized Basic EPS | -129.07% | 960.00% | |||
| EPS Diluted | -3,412.00% | 125.00% | |||
| Normalized Diluted EPS | -129.07% | 960.00% | |||
| Average Basic Shares Outstanding | -0.42% | 0.44% | |||
| Average Diluted Shares Outstanding | -0.42% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||